XTRA:MRKPharmaceuticals
China’s First-in-Class TGCT Drug Approval Might Change The Case For Investing In Merck (XTRA:MRK)
Merck KGaA, Darmstadt, Germany recently reported that China’s NMPA has granted Priority Review approval for pimicotinib, a CSF-1R inhibitor, to treat adult patients with symptomatic tenosynovial giant cell tumor where surgery risks functional limitation or relatively severe morbidity.
This first Chemical Drug Class 1 approval in China for TGCT, backed by strong Phase 3 MANEUVER data, adds a differentiated rare-disease therapy to Merck KGaA’s healthcare portfolio in a major market.
We’ll now...